Ceftazidime with avibactam (Zavicefta®)
General Information
Do NOT use if patient has a history of severe penicillin allergy. If in doubt, discuss with Micro/ID.
Restricted formulary antimicrobial: For details see OUH netFormulary
AWaRe antibiotic classification: 'Reserve'. All indications to be discussed with Micro/ID.
Renal and hepatic impairment
Renal impairment
|
Creatinine Clearance (mL/min) |
Dose regimen |
Frequency |
|
31-50 |
1g ceftazidime/0.25 g avibactam (1.25 g) |
Every 8 hours |
|
16-30 |
750 mg ceftazidime/187.5 mg avibactam (937.5 mg) |
Every 12 hours |
|
6-15 |
750 mg ceftazidime/187.5 mg avibactam (937.5 mg) |
Every 24 hours |
|
End stage renal disease including on haemodialysis |
750 mg ceftazidime/187.5 mg avibactam (937.5 mg) |
Every 48 hours |
- Dialysed: give after dialysis.
Note: dose ranges use creatinine clearance, rather than eGFR.
Hepatic impairment
No dosage adjustment required
Pregnancy and breastfeeding
Pregnancy
Use only if benefits outweigh the risk in pregnancy
Breastfeeding
Discuss with pharmacy.
Additional information
- Ceftazidime and Avibactam 2.5 g vial contains 2 g Ceftazidime and 0.5 g Avibactam powder for concentrate for solution for infusion.
- Each vial contains a total of 6.44 mmol of sodium (approximately 148 mg). This should be considered when administering to patients who are on a controlled sodium diet.
References
- Summary of Product Characteristics (SPC) for Zavicefta 2g/0.5g Powder for concentration for solution for Infusion. Accessed via www.medicines.org.uk 26/03/18. Last updated 06/02/18